Figure 1.

(A) In situ oxidase activity of ceruloplasmin oxidase among health donor, heterozygous carriers and homozygous WD patients. The patient (WD) had been undergoing therapy while S and B were diagnosed as health individuals and asymptomatic subjects; however, B started onset six month later. Two paternal samples referred to as F and M, respectively. Marker: protein marker, Std: commercial ceruloplasmin as standard. Albumin is naturally presented as the blue bands after conducting the assay. (B) Levels of protein carbonylation. Significantly increased expression of carbonylated proteins were observed in the samples of WD and B compared to the control. Albumin in the lower panels was utilized as a loading control.